PHARMACEUTICAL LICENSING OVERVIEW- MARKET RESEARCH REPORTS ON AARKSTORE ENTERPRISE
Introduction
Big Pharma continues to restructure the inner R&D departments as partial of drawn out cost-cutting measures to assistance revoke the stroke of the imminent 2011 obvious cliff. To fill tube voids with brand new products, companies go upon to have acquisitions as well as form partnerships with tiny pharma, biotech companies as well as academia, nonetheless the relations in between any have been apropos increasingly dynamic.
Scope
*Overview of Big Pharma’s stream as well as approaching destiny faith upon outwardly sourced products
*Overview of drivers as well as resistors of chartering deals as well as an comment of pass trends as well as factors which will figure the destiny make-up of licensing
*Analysis of pass product deals during 2008-09, analyzing trends for in-licensing, out-licensing as well as manufacturing/supply arrangements
*Assessment of drug find as well as record deals done by the tip 10 curative companies during 2008-09
Highlights
The series of in-licensing deals in 2009 augmenting by 12% over 2008, confirming which Big Pharma is actively looking acquisitions as well as chartering agreements as the some-more cost-effective equates to of gaining entrance to novel products than carrying out endless in-house R&D.
Although deals for drug during the beginning stages of expansion accounted for roughly 60% of all product in-licensing deals analyzed, Big Pharma severely augmenting the thoroughness upon Phase II as well as III products in 2009 as it looks to equivalent the 2011 obvious precipice by incorporating some-more advanced-stage products in to the pipelines to raise short/mid-term growth.
GlaxoSmithKline was by distant the many active Big Pharma player. While many of the Big Pharma peers have participated in vast M&A deals over the past 2 years, GlaxoSmithKline has to illustrate distant elite to thoroughness upon incorporating outwardly acquired products in to the pipeline.
Reasons to Purchase
*Appreciate the drivers as well as resistors companies face when chartering products, as well as the following strategies the little companies have been employing
*Identify befitting pharma partners to aim when deliberation out-licensing your technologies as well as products
*Understand the citation the all the time elaborating curative chartering landscape is relocating in sequence to brand the many appropriate strategies to succeed
Table of Contents :
“ABOUT HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
Geographic specific reports: 2
Global emanate reports: 2
1. About This Report 3
Chapter make up 4
Executive outline 4
Licensing trends general opinion 4
Evolving trends in the chartering landscape 4
Product chartering deals as well as trends 4
Technology chartering deals as well as trends 4
Bibliography 4
Contributing experts 5
Related reports 5
Upcoming compared reports 5
2. Executive Summary 6
Strategic scoping as well as thoroughness 6
Key commentary 6
Key definitions 8
Deal definitions 8
Company classifications 8
Explanation of launch/core/expiry investigate 8
Table of Contents 9
3. Licensing Trends Overview 10
Key commentary 10
Big Pharma trends 11
Big Pharma’s faith upon outwardly sourced products drives sales expansion 11
Big Pharma’s sourcing of outmost products is set to grow 12
AstraZeneca to spin some-more reliant upon in-licensed products as inner products face general foe 13
Abbott’s new M&A wake up will revoke faith upon in-licensed products 14
Pfizer’s merger of Wyeth will see it some-more reliant upon sales from in-licensed products 15
Licensing understanding trends 17
Annual shift in understanding wake up 17
Big Pharma increases series of in-licensing deals during 2009 17
Cash-rich Big Pharma capitalized upon mercantile incident by second half of 2009 18
Deals by theme 19
The infancy of Big Pharma’s chartering wake up focuses upon deals for drug possibilities 19
Deals by association 20
GlaxoSmithKline was the many active Big Pharma player 20
GlaxoSmithKline lifted the spin of in-licensing wake up in the second half of 2009 21
Eli Lilly to thoroughness upon inner R&D capabilities rsther than than externally-sourced products 22
4. Evolving Trends in the Licensing Landscape 23
Key commentary 23
Introduction 24
Both Pharma as well as Biotech face the same core hurdles 24
Drivers as well as resistors of chartering 25
Big Pharma’s inner R&D predicament drives chartering query 26
Poor earnings from Pharma’s inner R&D the confounding emanate 26
Widespread cost-saving measures as well as necessary refocusing executive to Big Pharma’s streamlined R&D 27
Biopharma’s needs to combine have been plural 27
Big Pharma’s money as well as imagination is necessary to allege Biopharma’s tube possibilities 28
Alliances concede companies to share the price as well as fundamental risks of drug expansion 28
Accessing outmost resources as well as capabilities 29
Future opinion for chartering deals 30
Big Pharma expansion 30
Partnership agreements spin some-more perplexing as licensees demeanour to share expansion risk 30
How distant can Big Pharma take the cost-cutting strategies? 30
Big Pharma’s near-term thoroughness 32
Late-and mid-stage understanding wake up set to enlarge as Pharma looks to equivalent the obvious precipice 32
Deals with academia to greaten as well as spin some-more formidable 33
Pharma will spin increasingly to universities for early-stage creation 33
Closer partnership will revoke educational counsel 34
Niche indications as well as waif drug have been tasteful chartering propositions 35
Smaller studious populations equivalent by tasteful mercantile incentives 35
GlaxoSmithKline as well as Pfizer uncover larger thoroughness upon waif drug 36
Push towards personalized disinfectant will figure record deals 36
Strategic chartering options accessible for Pharma in flourishing diagnostics marketplace 36
Big Pharma out-licensing to enlarge as inner R&D thoroughness is realigned 38
Big Pharma divestitures could paint opportunities for not as big companies 38
Early-stage understanding make up changes prominence Big Pharma’s hatred to shouldering risk 39
Smaller upfront fees as well as one some-more miracle payments reinstate vast opening values for riskier early-stage products 39
Option-based deals – the low-cost process of securing rights to potentially innovative early-stage products 40
Big Pharma’s dilettante outmost arms paint an pick approach to deposit in as well as soak up creation 42
Big Pharma try as well as choice supports yield an additional track to group up with biotechs 42
GlaxoSmithKline’s Centre of Excellence for External Drug Discovery focuses upon option-based deals 43
Focus upon rising markets will enlarge 43
Regional rights sought to fuel pull in to rising markets 43
Middle East to spin the pass source of creation in years to come 44
5. Product Licensing Deals as well as Trends 45
Key commentary 45
Pharmaceutical chartering trends 46
In-licensing trends 46
Deals by first idea 46
Research as well as find as well as product permit deals many renouned understanding sorts for Big Pharma 46
Deals by care area 47
Infectious diseases is the many usual care area for Big Pharma’s product in-licensing deals 47
Influenza vaccine developments conduct anti-infective in-licensing deals 49
Central shaken complement deals thoroughness upon the presentation of biologic treatments for Alzheimer’s mildew as well as suffering 50
GlaxoSmithKline as well as Sanofi-Aventis up their thoroughness upon in-licensing oncology possibilities in 2009 52
Deals by theatre of expansion 54
Research/discovery theatre products paint some-more than the third of all product in-licensing deals done by Big Pharma 54
Big Pharma moves the courtesy to in-licensing products during some-more modernized stages of expansion 55
Full permit agreements form the infancy of clinical theatre product in-licensing deals 56
Marketing, graduation as well as placement deals many ordinarily compared with marketed products 57
Deals by worth – upfront price paid 57
A reward upfront price is customary for drug possibilities which have reached Phase III expansion 57
Deals for executive shaken complement drug ordered the top upfront fees during 2008-09 58
Deals by drug sort 60
Small molecules sojourn the categorical aim of in-licensing deals among augmenting thoroughness upon biologics 60
Pfizer leads the approach in branch dungeon care deals as Big Pharma in all refrains from mass investment 62
Deals by heading dealmakers 63
GlaxoSmithKline leads the margin in conditions of product in-licensing deals 63
Abbott as well as Roche shorten product chartering deals as courtesy turns to mega-merger wake up 64
Eli Lilly, Sanofi-Aventis as well as Roche thoroughness upon securing the full chartering rights to the product 65
Johnson & Johnson ties up the biggest suit of investigate as well as find deals 65
All Big Pharma companies in-license products opposite the operation of care areas 67
Roche as well as Eli Lilly’s in-licensing deals thoroughness upon tiny molecules with biologic possibilities mostly acquired by M&A wake up 69
GlaxoSmithKline focuses upon appropriation vaccines whilst Sanofi-Aventis leads the approach in monoclonal antibody deals 70
Deals by source association sort 72
The smallest pharma/biotech companies have been the source of many in-licensed products 72
Vast infancy of deals with mid-sized as well as associate Big Pharma companies have been for selling rights 73
Deals by segment 74
2009 saw the poignant enlarge in product in-licensing deals for specific regions 74
Middle East approaching to spin the pass source of creation in years to come 75
Out-licensing trends
Read Also
Pages: 1 2
Tags: Aarkstore, Enterprise, Licensing, Market, overview, Pharmaceutical, reports, Research